Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for Gyre Therapeutics (GYRE) over the last 12 years, with Q3 2025 value amounting to $866000.0.

  • Gyre Therapeutics' Non-Current Deffered Revenue rose 36810.81% to $866000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $866000.0, marking a year-over-year increase of 36810.81%. This contributed to the annual value of $928000.0 for FY2024, which is 33568.08% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Non-Current Deffered Revenue of $866000.0 as of Q3 2025, which was up 36810.81% from $884000.0 recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Non-Current Deffered Revenue high stood at $928000.0 for Q4 2024, and its period low was $118000.0 during Q4 2022.
  • In the last 4 years, Gyre Therapeutics' Non-Current Deffered Revenue had a median value of $213000.0 in 2023 and averaged $499333.3.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first skyrocketed by 8050.85% in 2023, then surged by 36810.81% in 2025.
  • Gyre Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $118000.0 in 2022, then soared by 80.51% to $213000.0 in 2023, then skyrocketed by 335.68% to $928000.0 in 2024, then dropped by 6.68% to $866000.0 in 2025.
  • Its Non-Current Deffered Revenue was $866000.0 in Q3 2025, compared to $884000.0 in Q2 2025 and $905000.0 in Q1 2025.